Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:EMISNASDAQ:FLXNNYSE:KDMNNASDAQ:TXMDOTCMKTS:VEGPF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsTXMDTherapeuticsMD$1.87-2.6%$2.23$1.86▼$4.73$21.56M1.0321,127 shs10,553 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/A5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%KDMNKadmon0.00%0.00%0.00%0.00%0.00%TXMDTherapeuticsMD-2.60%-1.58%-16.89%-17.62%-47.03%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics0.3021 of 5 stars0.00.00.04.30.01.70.6KDMNKadmonN/AN/AN/AN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMISEmisphere TechnologiesN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/ATXMDTherapeuticsMD2.00HoldN/AN/AVEGPFVectura GroupN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82KDMNKadmonN/AN/AN/AN/AN/AN/ATXMDTherapeuticsMD$1.30M16.59N/AN/A$2.77 per share0.68VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/ATXMDTherapeuticsMD-$10.28MN/A0.00∞N/AN/A-25.54%-14.87%5/20/2024 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMISEmisphere TechnologiesN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05KDMNKadmonN/AN/AN/ATXMDTherapeuticsMDN/A1.721.72VEGPFVectura GroupN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMISEmisphere TechnologiesN/AFLXNFlexion Therapeutics90.01%KDMNKadmonN/ATXMDTherapeuticsMD30.74%VEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipEMISEmisphere Technologies72.90%FLXNFlexion Therapeutics9.13%KDMNKadmonN/ATXMDTherapeuticsMD1.20%VEGPFVectura GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableKDMNKadmonN/A178.52 millionN/AOptionableTXMDTherapeuticsMD111.53 million11.39 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableTXMD, VEGPF, EMIS, FLXN, and KDMN HeadlinesSourceHeadlineCritical Review: Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF)americanbankingnews.com - April 20 at 1:26 AMEuropean Stocks See Mixed Session as U.K.'s FTSE Leadsthestreet.com - January 16 at 11:20 PMVECTURA GROUP LS -,000271 (V4TA.BE)finance.yahoo.com - January 15 at 2:59 PMVectura Group PLC (V4TA.BE)finance.yahoo.com - January 9 at 10:12 AMResults for 'Vectura-Fertin Pharma'afaqs.com - October 11 at 7:33 PMVectura Group (OTC:VEGPF), Short Interest Reportbenzinga.com - July 18 at 11:14 PMCarlyle stays in race for Vecturauk.finance.yahoo.com - August 27 at 12:54 PMForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826finance.yahoo.com - August 27 at 6:38 AMPhilip Morris chief attacks critics as Vectura bid tests investorsuk.finance.yahoo.com - August 20 at 2:24 AMMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closeruk.finance.yahoo.com - August 13 at 4:18 AMVectura auction called off after Carlyle declines to beat Philip Morris biduk.finance.yahoo.com - August 10 at 3:02 PMUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorfinance.yahoo.com - August 9 at 8:04 AMPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringca.finance.yahoo.com - August 9 at 8:04 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.KadmonNYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.TherapeuticsMDNASDAQ:TXMDTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Vectura GroupOTCMKTS:VEGPFVectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.